Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barr syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Akari Therapeutics, Plc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DATA HIGHLIGHTS ABILITY OF AKARI'S ADC PAYLOAD, PH1, TO SUPPRESS THE LEVELS OF THE AR-V7 RECEPTOR THAT IS RESPONSIBLE FOR DRIVING HORMONE REFRACTORY PROSTATE CANCER PROGRESSION

AKARI THERAPEUTICS' PRECLINICAL DATA DEMONSTRATES THE POTENTIAL OF ITS NOVEL ADC SPLICEOSOME MODULATING PAYLOAD, PH1

BOSTON AND LONDON, SEPT. 17, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT IT HAS FILED A PROVISIONAL PATENT APPLICATION WITH THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) COVERING THE COMPANY'S ANTIBODY DRUG CONJUGATE (ADC) PLATFORM USING AKARI'S SPLICEOSOME PAYLOAD PH1 FOR TREATING CANCER BY MODULATING ALTERNATIVE SPLICING WITHIN CANCER CELLS. THIS PATENT APPLICATION REPRESENTS A NEW PATENT FAMILY TO FURTHER EXTEND AKARI'S PROPRIETARY POSITION WITH RESPECT TO THE COMPANY'S NOVEL PAYLOAD, PH1 (A NOVEL THAILANSTATIN ANALOG).

AKARI THERAPEUTICS ANNOUNCES FILING FOR NEW PATENT FOR NOVEL ADC PLATFORM UTILIZING SPLICEOSOME PAYLOAD PH1 FOR THE TREATMENT OF CANCER

BOSTON AND LONDON, SEPT. 05, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT ABIZER GASLIGHTWALA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF AKARI THERAPEUTICS WILL PRESENT AT THE H.C. WAINWRIGHT 27 TH ANNUAL GLOBAL INVESTMENT CONFERENCE BEING HELD FROM SEPTEMBER 8-10, 2025 IN NEW YORK, NY.

AKARI THERAPEUTICS TO PRESENT AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

LIVE MODERATED WEBCAST ON THURSDAY, SEPTEMBER 4 TH AT 4:00 PM ET ACCESS THE EVENT HERE BOSTON AND LONDON, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL IMMUNO-ONCOLOGY PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS) FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE VIRTUAL INVESTOR CLOSING BELL SERIES ON THURSDAY, SEPTEMBER 4, 2025 AT 4:00 PM ET.

AKARI THERAPEUTICS TO PARTICIPATE IN THE VIRTUAL INVESTOR CLOSING BELL SERIES

BOSTON AND LONDON, AUG. 14, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), A BIOTECHNOLOGY COMPANY DEVELOPING NOVEL ANTIBODY DRUG CONJUGATES (ADCS) WITH IMMUNO-ONCOLOGY PAYLOADS FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT IT WILL PRESENT AT THE WEBULL FINANCIAL CORPORATE CONNECT WEBINAR SERIES: BIOTECH/MEDTECH BEING HELD VIRTUALLY AUGUST 19-21, 2025. DETAILS FOR THE PRESENTATION ARE AS FOLLOWS: DATE AND TIME: TUESDAY, AUGUST 19, 2025 AT 2:00 PM ET PRESENTER: ABIZER GASLIGHTWALA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF AKARI REGISTRATION LINK: HERE ABOUT WEBULL FINANCIAL WEBULL FINANCIAL IS A LEADING ONLINE BROKERAGE PLATFORM COMMITTED TO EMPOWERING SELF-DIRECTED INVESTORS WITH INNOVATIVE TOOLS AND CUTTING-EDGE TECHNOLOGY.

AKARI THERAPEUTICS TO PRESENT AT THE WEBULL FINANCIAL CORPORATE CONNECT WEBINAR SERIES: BIOTECH/MEDTECH

ABIZER GASLIGHTWALA, PRESIDENT AND CEO OF AKARI THERAPEUTICS DISCUSSED AKARI'S COMMITMENT TO CONTINUED RESEARCH TO BETTER UNDERSTAND THE MULTIPLE EFFECTS OF ITS NOVEL SPLICEOSOME MODULATOR, PH1 ABIZER GASLIGHTWALA, PRESIDENT AND CEO OF AKARI THERAPEUTICS DISCUSSED AKARI'S COMMITMENT TO CONTINUED RESEARCH TO BETTER UNDERSTAND THE MULTIPLE EFFECTS OF ITS NOVEL SPLICEOSOME MODULATOR, PH1

AKARI THERAPEUTICS RELEASES VIRTUAL INVESTOR WHAT THIS MEANS SEGMENT

PH1 MODULATES RNA SPLICING, CAUSING CANCER CELL DEATH WHILE ACTIVATING THE IMMUNE SYSTEM TO ATTACK CANCER THROUGHOUT THE BODY

AKARI THERAPEUTICS CONTINUES KEY RESEARCH ON ITS NOVEL ANTIBODY DRUG CONJUGATE PAYLOAD PH1 TO FURTHER DEMONSTRATE ITS UNIQUE ABILITY TO TARGET CANCERS FUELED BY ONCOGENIC DRIVERS

BOSTON AND LONDON, JULY 22, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL IMMUNO-ONCOLOGY PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS) FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED ABIZER GASLIGHTWALA, DIRECTOR, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF AKARI, PARTICIPATED IN THE VIRTUAL INVESTOR WHAT'S YOUR STORY SUMMER SPOTLIGHT ON-DEMAND CONFERENCE. AS PART OF THE EVENT, MR.

AKARI THERAPEUTICS PARTICIPATES IN THE VIRTUAL INVESTOR WHAT'S YOUR STORY SUMMER SPOTLIGHT ON-DEMAND CONFERENCE

ACCESS THE WHAT THIS MEANS SEGMENT HERE BOSTON AND LONDON, JUNE 25, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL IMMUNO-ONCOLOGY PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS) FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED IT RECENTLY PARTICIPATED IN A VIRTUAL INVESTOR WHAT THIS MEANS SEGMENT. FOR THE SEGMENT, ABIZER GASLIGHTWALA, PRESIDENT AND CEO OF AKARI THERAPEUTICS DISCUSSED THE COMPANY'S RECENTLY ISSUED INDIA PATENT NO.

AKARI THERAPEUTICS RELEASES VIRTUAL INVESTOR WHAT THIS MEANS SEGMENT HIGHLIGHTING ITS RECENTLY GRANTED INDIA PATENT

DIFFERENTIATED PH1 PAYLOAD IS A SPLICEOSOME INHIBITOR DESIGNED TO INHIBIT RNA SPLICING, LEADING TO CANCER CELL DEATH AND ACTIVATION OF IMMUNE SYSTEM THROUGH MULTIPLE MECHANISMS

AKARI THERAPEUTICS BOLSTERS GLOBAL IP ESTATE FOR ITS NOVEL ANTIBODY DRUG CONJUGATE (ADC) IMMUNO-ONCOLOGY PAYLOAD, PH1, WITH RECENT GRANTING OF PATENT PROTECTION ACROSS INDIA

Akari Therapeutics, Plc

AKTX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Akari Therapeutics, Plc

AKTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AKTX